MD
MDRX.US Veradigm Inc.
- Market cap
- USD 517M
- P/E
- -
- P/B
- 0.68x
- ROE
- -8.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is MDRX.US undervalued?
Graham numberThe Graham number of Veradigm Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Veradigm Inc. fundamental analysis
No fundamental analysis for Veradigm Inc. yet.
Veradigm Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Veradigm Inc.
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include e…
Full company profileVeradigm Inc. financial statements
Veradigm Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.38B | 1.39B | 1.55B | 1.50B | 1.75B | 1.63B | 1.50B | 577M | 588M | 588M |
| Gross Profit | 546M | 557M | 645M | 633M | 725M | 575M | 566M | 258M | 308M | 308M |
| Operating Income | -39.2M | 31.9M | 67.7M | 12.5M | -95.1M | -99.7M | -57.7M | 75.7M | -19.6M | -27.1M |
| EBITDA | 135M | 192M | 197M | 4.83M | 172M | 12.0M | 109M | 243M | 58.4M | 58.4M |
| Net Income | -66.5M | -2.23M | -25.7M | -196M | 364M | -182M | 700M | 134M | -86.5M | -86.5M |
| EPS | -0.37 | -0.01 | -0.14 | -1.09 | 2.04 | -1.10 | 4.40 | 0.97 | -0.67 | -0.67 |
| Balance Sheet | ||||||||||
| Total Assets | 2.46B | 2.68B | 3.83B | 4.23B | 3.18B | 3.21B | 2.92B | 2.43B | 1.50B | 1.50B |
| Total Liabilities | 1.18B | 1.26B | 2.17B | 2.64B | 1.60B | 1.92B | 1.25B | 1.02B | 487M | 487M |
| Shareholders' Equity | 1.28B | 1.42B | 1.23B | 1.12B | 1.58B | 1.29B | 1.67B | 1.41B | 1.02B | 1.02B |
| Cash & Short-term Investments | 53.2M | 117M | 95.6M | 119M | 174M | 130M | 531M | 188M | 447M | 447M |
| Total Debt | 567M | 625M | 1.33B | 938M | 669M | 1.03B | 283M | 373M | - | 219M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 103M | 212M | 269M | 279M | 67.9M | 46.3M | -107M | -75.4M | 116M | 116M |
| Capital Expenditure | 67.1M | 67.6M | 138M | 157M | 145M | 128M | 17.0M | 1.89M | 32.3M | 32.3M |
| Free Cash Flow | 36.4M | 144M | 131M | 122M | -76.7M | -81.7M | -124M | -77.3M | 83.3M | 83.3M |
| Ratios | ||||||||||
| ROE | -5.2% | -0.2% | -2.1% | -17.5% | 23.0% | -14.2% | 42.0% | 9.5% | -8.5% | -8.5% |
| ROA | -2.7% | -0.1% | -0.7% | -4.6% | 11.4% | -5.7% | 24.0% | 5.5% | -5.7% | -5.7% |
| Net Profit Margin | -4.8% | -0.2% | -1.7% | -13.1% | 20.8% | -11.2% | 46.6% | 23.3% | -14.7% | -14.7% |
| Debt to Equity | 0.44x | 0.44x | 1.08x | 0.84x | 0.42x | 0.80x | 0.17x | 0.26x | - | 0.22x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Veradigm Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Oct 7, 2008
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 580M | 3.25 | 159.5% |
| 2017 | USD 375M | 2.07 | - |
| 2016 | USD 1.16B | 6.21 | - |
| 2015 | - | - | - |
| 2014 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Veradigm Inc.
- Insiders 4.43%
- Institutions 62.23%
- Public & others 33.34%
- Shares outstanding 109M
- Free float 81.2M
Top funds holding MDRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Explorer Value Inv | 848K | 0.78% | +20.71% | Jun 2026 |
| Hartford Small Cap Value Y | 550K | 0.50% | 0.00% | Jul 2026 |
| Royce Micro-Cap Trust | 490K | 0.45% | +428.47% | Jun 2026 |
| NYLIM VP Wellington Small Cap Initial | 228K | 0.21% | 0.00% | Jul 2026 |
| Royce Micro-Cap Invmt | 206K | 0.19% | +375.19% | Jun 2026 |
| Royce Small-Cap Trust | 154K | 0.14% | 0.00% | Jun 2026 |
| Wellington Absolute Return Global Equity | 67.9K | 0.06% | 0.00% | Mar 2026 |
| Wellington ARGE (Hedged to GBP) | 67.9K | 0.06% | 0.00% | Mar 2026 |
| Royce Capital Micro-Cap Inv | 67.8K | 0.06% | +387.87% | Jun 2026 |
| Wellington Hedged Alpha Opportunities | 49.6K | 0.05% | 0.00% | Mar 2026 |
| Adirondack Small Cap | 41.2K | 0.04% | -33.09% | Jun 2026 |
| Wellington Sm Cap Value Opportunities | 37.1K | 0.03% | -12.07% | Jun 2026 |
| BSF Systematic US Eq Abs Ret A2 USD | 22.9K | 0.02% | 0.00% | Dec 2025 |
| Acclivity Small Cap Value I | 3.97K | 0.00% | 0.00% | Jun 2026 |
| Dynamic Outcome Target Strategy | 6.00 | 0.00% | 0.00% | Jun 2026 |
Top institutions holding MDRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FNY Investment Advisers, LLC | 13.0K | 0.01% | 0.00% | Mar 2026 |
| Huntington National Bank | 1.00 | 0.00% | 0.00% | Mar 2026 |
Veradigm Inc. company profile
- Company name
- Veradigm Inc.
- Ticker
- MDRX.US
- Exchange
- USA Stocks
- Listed since
- Jul 26, 1999
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 2,300
- Fiscal year end
- December
- Address
- 222 Merchandise Mart Plaza, Chicago, IL, United States, 60654
- Phone
- 800 334 8534
- Website
- veradigm.com
About Veradigm Inc.
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS, EHR software, veradigm EHR, and practice fusion EHR; and patient engagement platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as veradigm connect, veradigm app expo, and diagnostic ordering and resulting network; life sciences, health plans and payers, and providers; and veradigm eprescribe enterprise. In addition, the company offers risk adjustment solutions, such as health equity analytics, risk adjustment analytics, risk mitigator, comprehensive submissions, and utilization analytics; quality analytics, risk adjustment, and quality management; clinical data exchange and coding solutions, including echart courier, echart coder, and echart integration and analytics; clinical data registries for physicians and veradigm payer insights; provider engagement solutions; care gap alerting, gap closure services, and veradigm payerpath solutions. Further, it provides real world data solutions, such as NLP-enriched EHR data solutions, and clinical data registries; real world evidence and real-world evidence analytics platform; and digital health media solutions. Additionally, the company serves physician practices, hospitals, laboratory and radiology centers, urgent care facilities, health IT companies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
Veradigm Inc. management
10- Mr. Donald D. TriggChief Executive Officer & Director · born 1972
- Mr. Christian GreyenbuhlChief Financial Officer
- Mr. Tehsin SyedChief Product & Technology Officer · born 1977
- Mr. Steven Paul HalperVice President of Investor Relations
- Mr. Eric JacobsonSenior VP, Interim General Counsel & Corporate Secretary · born 1975
- Mr. Richard ElmoreSenior Vice President of Corporate Development & Strategy
- Ms. Tally BakerChief Human Resources Officer · born 1982
- Mr. John SageSenior Vice President of U.S. Hospitals & Health Systems Sales
- Mr. Elliot BryantSenior VP & General Manager for Classic Client Solutions Business Unit
- Mr. John MayrSenior Vice President of Global Client Delivery Organization